Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma
Year: 2025
Type: article
Abstract: Relapsed and refractory multiple myeloma (RRMM) has a poor median overall survival (OS) of 13 months [ 1 ]. The two FDA-approved CAR-Ts targeting B-cell maturation antigen (BCMA) for RRMM are Idecabtagene Vicleucel (ide-cel) [ 2 , 3 ] and Ciltacabtagene Autoleucel (cilta-cel), with subsequent real-world consortium data [ 4 ] showing improvement in overall survival and progression-free survival. However, similar to anti-CD19 CAR-Ts, the anti-BCMA CAR-Ts carry frequent and serious adverse events, such as cytokine release syndrome (CRS), characterized by fever and various degrees of hemodynamic compromise, and end-organ damage [ 5 ].
Source: Blood Cancer Journal
Authors: Stefanie Palfi, Lauren C. Peres, Himara Koelmeyer, Melissa Alsina, Rachid C. Baz, Brandon J. Blue, Salvatore Corallo, Gabriel De Avila, Ciara Freeman, Rebecca Gonzalez, Ariel Grajales-Cruz, Kristy Harvey, Hien D. Liu, Taiga Nishihori, Guilherme H. Oliveira, Laura B. Oswald, Omar Castaneda Puglianini, Sruthi Selvakumar, Alexis Behne Sharma, Elicia Wang, Kenneth H. Shain, Michael Jain, Frederick L. Locke, Mohammed Alomar, Doris K. Hansen, Dae Hyun Lee
Institutions: University of South Florida, Moffitt Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,290
OpenAlex ID: W4409435244